A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects
with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and
expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics,
biomarkers, and efficacy.